| Literature DB >> 29065558 |
Tsang-Hsiung Lin1, Hsing-Hao Su2, Hong-Yo Kang3,4, Tsung-Hsien Chang5,6.
Abstract
The original hygiene hypothesis declares "more infections in early childhood protect against later atopy". According to the hygiene hypothesis, the increased incidence of allergic disorders in developed countries is explained by the decrease of infections. Epithelial cells and dendritic cells play key roles in bridging the innate and adaptive immune systems. Among the various pattern-recognition receptor systems of epithelial cells and dendritic cells, including toll-like receptors (TLRs), nucleotide-binding oligomerization domain (NOD)-like receptors (NLRs) and others, TLRs are the key systems of immune response regulation. In humans, TLRs consist of TLR1 to TLR10. They regulate cellular responses through engagement with TLR ligands, e.g., lipopolysaccharides (LPS) acts through TLR4 and dsRNA acts through TLR3, but there are certain common components between these two TLR pathways. dsRNA activates epithelial cells and dendritic cells in different directions, resulting in allergy-related Th2-skewing tendency in epithelial cells, and Th1-skewing tendency in dendritic cells. The Th2-skewing effect by stimulation of dsRNA on epithelial cells could be suppressed by the presence of LPS above some threshold. When LPS level decreases, the Th2-skewing effect increases. It may be via these interrelated networks and related factors that LPS modifies the allergic responses and provides a plausible mechanism of the hygiene hypothesis. Several hygiene hypothesis-related phenomena, seemingly conflicting, are also discussed in this review, along with their proposed mechanisms.Entities:
Keywords: allergic respiratory disorder; dendritic cell; double-stranded RNA; epithelial cell; hygiene hypothesis; lipopolysaccharide; respiratory syncytial virus; rhinovirus; toll-like receptor
Mesh:
Substances:
Year: 2017 PMID: 29065558 PMCID: PMC5666898 DOI: 10.3390/ijms18102219
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Studies demonstrating the biphasic capacity of lipopolysaccharides (LPS).
| Authors | Model | Origin of LPS | LPS Dose and Pathway Used | Allergen or Antigen | Allergen Dose and Pathway Used for Sensitization | Allergen Dose and Pathway Used for Challenging | Protocol | Result | Note |
|---|---|---|---|---|---|---|---|---|---|
| Tulic et al., 2000 [ | male PVG rat | 50 μg/mL inhaled | OVA | 100 μg/mL i.p. | Aerosolized 1% OVA at Day 11 after sensitization | Sensitized rats exposed 1 d before or 1, 2, 4, 6, 8, 10, or 12 d after sensitization A second group of sensitized rats were exposed to LPS 18 h after OVA challenge. | Single aerosol exposure to LPS—1 d, and up to 4 d after i.p. OVA protected against allergy. LPS exposure ≥6, 8, or 10 d after sensitization exacerbated the allergy with cellular influx. Exposure of sensitized rats to LPS on Day 12, 18 h after allergen challenge further potentiated the allergen induced inflammatory cell influx, predominantly due to a 20-fold increase in neutrophil influx, making up ≥80% of the cellular content. | Timing of LPS exposure determines protection or exacerbation of allergy. | |
| Eisenbarth et al., 2002 [ | BALB/cJ mice and BALB/cAnNCr | Concomitant use of 100 μg (high dose) or 0.1 μg LPS with OVA in sensitizing period | OVA | 100 μg OVA in 50 μL PBS intranasally, or 100 μg OVA in 2 mg Al(OH)3 intraperitoneally, with LPS depletion | 25 μg OVA intranasally | Sensitized on Days 0, 1 and 2, challenged on Days 14,15,18 and 19, killed on Day 21 | Mice exposed to LPS-depleted OVA showed no airway inflammatory responses after challenge; those sensitized with OVA containing low dose LPS demonstrated significant Th2 lung infiltrates; those exposed to PBS or low dose LPS alone did not generate pulmonary inflammation after challenge; those sensitized with OVA containing high dose LPS resulted in a Th1 associated response. | TLR4 signaling Is required for Th2 priming to inhaled antigens, and the dose of LPS during sensitizing period regulates the predominance of Th1 or Th2 response. | |
| Lowe et al., 2015 [ | Male Dunkin-Hartley guinea pigs (GPs) | LPS source not mentioned | Inhaled 30 μg/mL | OVA | Bil. i.p. injection of OVA,150 μg/mL and Al(OH)3 100 mg/mL normal saline | Sensitized GPs were exposed to inhaled OVA (300 μg/mL) on Day 21. | LPS (30 μg/mL) exposure was by two protocols: 72 and 24 h pre-OVA exposure, 48 h pre-OVA and co-administered with OVA by nebulizer, at rate of 0.3 mL/min for 1 h | LPS exposure 24 h before allergen challenge attenuates the early asthmatic response (EAR), whereas co-administered LPS does not influence the EAR. The addition of a second LPS exposure co-administered with OVA prolonged the EAR. Similarly, LPS exposure 24 h before allergen challenge diminished airway hyperreactivity (AHR) to histamine, whereas co-administered LPS prolonged the AHR | Emphasizing to the timing of LPS application |
| Langenkamp et al., 2000 [ | Dendritic cells | Toxic shock syndrome toxin-1 (TSST-1) | 20–100 ng/mL LPS 0.1 or 10 ng/mL TSST-1 | TSST-1 as antigen | Pretreatment of dendritic cells with LPS, then after 8 or 48 h, 0.1 or 10 ng/mL TSST-1 was added to culture medium | Soon after LPS stimulation DCs primed strong Th1 responses, but later favored Th2 responses. High dose antigen favored Th1 response, yet low dose antigen favored Th2 response. Exogenous IL12 favored Th1 tendency, yet IL4 favored Th2. | This study explored DC’s priming tendency after LPS pre-stimulation, in response to superantigen TSST-1, which was an inflammatory response, but not allergic response. |
d: days.
Studies demonstrating the protective capacity of LPS.
| Authors | Model | Origin of LPS | LPS Dose and Pathway Used | Allergen, Antigen or Stimulus | Allergen Dose and Pathway Used for Sensitization | Allergen Dose and Pathway Used for Challenging | Protocol | Result | Note |
|---|---|---|---|---|---|---|---|---|---|
| Carlsten et al., 2011 [ | Human of age 7 | Home dust | Inhaled from environment | Dog allergen | Inhaled from environment | Inhaled from environment | Correlation study | Endotoxin was associated with decreased risk of sensitization to dog allergen. | HDM was also associated with decreased risk of sensitization to dog allergen, which needs further confirmatory studies. However, in Schuijs’ study below, HDM was noted to induce A20 also, though less pronounced than LPS. |
| Braun-Fahrlander et al., 2002 [ | Human of age 6-13 | Home dust | Inhaled from environment | unspecified | Inhaled from environment | Inhaled from environment | Correlation study | Endotoxin levels in dust were inversely related to the incidence of hay fever, atopic asthma, and atopic sensitization. | |
| Schuijs et al., 2015 [ | Female C57Bl/6 wild-type Human normal bronchial epithelial cells Human epithelial cells from asthma patients | Ultrapure LPS purchased from Invivogen. Strain and species not specified. | A single intranasal injection of 1 μg LPS on Day 14, or i.n 100 ng every other day (starting on Day 14). 100 ng overnight 100 ng every other day for 1 week | HDM | 1 μg HDM extracts No sensitization Accurate time point of sensitization could not be traced. | 10 μg HDM extracts HDM extracts (dose not mentioned) HDM extracts (dose not mentioned) | Mice sensitized on Day 0 with 1 μg HDM, and challenged on Days 7–11 with 10 μg HDM extracts Cells exposed overnight to 100 ng LPS. After 2 weeks, cells stimulated with HDM extract. cell cultures exposed to 100 ng of LPS for 1 week before stimulation with HDMs | Protective LPS led to decreasing of IL5 and IL13 in mediastinal lymph node cells and downregulation of HDM-induced recruitment of cDCs, with moDCs unaffected. LPS pretreatment reduced allergic cytokines production. | TLR4 signaling in ECs induces attenuators of signaling such as A20. |
| Ganesh et al., 2014 [ | BALB/c and DO11.10 mice | Intragastric inoculation with 0.5~1 × 109 CFU of whole | OVA | 10 μg OVA + adjuvant, i.p. | intranasal use of 30 μg of OVA | Mice were sensitized with OVA i.p. on Days 7, 8, 9, and 20, infected intragastrically with | This study used whole bacteria for experiment, instead of LPS only. | ||
| Rodriguez et al., 2003 [ | C57BL/6J, BALB/c and C3H/HeJ mice | LPS at a dose of 20 μg/animal was delivered intravenously concomitantly with a second OVA challenge | OVA | 4 μg OVA/1.6 mg aluminum hydroxide | 10 μg OVA/50 μL saline intranasally | Mice were immunized on Days 0 and 7, and challenged on Days 14 and 21 intranasally | LPS administration suppresses allergic airway inflammation and cytokine production through a mechanism independent of IL12 or IFNγ. Systemic LPS inhibited airway inflammation. Systemic LPS reduced airway hyperreactivity (AHR). | Thus, systemic LPS displayed protective effect, while local LPS displayed pro-inflammatory effect with neutrophilia reaction. | |
| Lin et al., 2016 [ | H292 cell line | 0.3 to 30 μg/mL co-culture | polyI:C, | LPS pretreatment 2 h before polyI:C or HPeV1 co-culture with H292 cells. | The downstream production of TSLP and IL33 by stimulating H292 cells with polyI:C or HPeV1 was reduced with 30 μg/mL LPS pretreatment, but not 0.3 μg/mL LPS |
Studies demonstrating the pro-inflammatory capacity of LPS.
| Authors | Model | Origin of LPS | LPS Dose and Pathway Used | Allergen or Antigen | Allergen Dose and Pathway Used for Sensitization | Allergen Dose and Pathway Used for Challenging | Protocol | Result | Note |
|---|---|---|---|---|---|---|---|---|---|
| Rittirsch et al., 2008 [ | C57BL/6 mice C57BL/6 mice with neutrophil depleted by antibody | 50 μg LPS in 40 μL PBS intratracheally, total 2,550,100 μg | nil | nil | nil | Permeability index checked from bronchoalveolar lavage at 0, 2, 4, 6, 8 h. | Maximal permeability at 50 μg, no different from 100 μg; at 6 h, no different from 8 h. When neutrophils depleted, no permeability change. Pathology includes: interstitial and intraalveolar deposits of neutrophils and fibrin, prominence of alveolar macrophages, and intraalveolar hemorrhage. | The LPS concentration used is 1250 μg/mL, as compared to the 0.3 and 30 μg/mL in cell line model [ | |
| Eutamene et al., 2005 [ | Male Wistar rats NCI-H292 human airway epithelial cells | 1 μg LPS per rat via intra-tracheal instillate 2 μg/mL LPS for co-culture | nil | nil | nil | LPS from LPS from | Airway epithelial paracellular permeability was increased
Myosin light chain (MLC) phosphorylation occurs after | ||
| Rojas et al., 2005 [ | C57BL/6 male mice | Intraperitoneally with 1 mg/kg LPS | nil | nil | nil | Mice were inoculated intraperitoneally with 1 mg/kg of LPS from | Sublethal dose of i.p. LPS to mice caused rapid onset of interstitial pulmonary edema, inflammatory cell accumulation, and deposition of fibronectin and collagen in the lungs. | The scale of mg/kg is sublethal, compared to the protective dose scale of ng/mL to μg/mL. | |
| Yao et al., 2017 [ | Male C57BL/6J mice male Wistar rats | LPS, source not specified | i.p. LPS at the doses of 8 mg/kg i.p. LPS at the doses of 5 mg/kg | nil | nil | nil | Lung injury in mice and rats were induced by i.p. LPS. | Lung tissues revealed interstitial edema and hemorrhage, alveolar wall thickening, increased infiltration of neutrophils and macrophages in the lung parenchyma and alveolar spaces. | Again, the dose of causing acute lung injury is on the scale of mg/kg. |
| Taveira da Silva et al., 1993 [ | Human | i.v. LPS | nil | nil | nil | The patient administered i.v. 1 mg of | Septic shock syndrome induced, including a high-cardiac-output hypotension, disseminated intravascular coagulation, abnormalities of hepatic and renal function, and non-cardiogenic pulmonary edema. | 1 mg of purified LPS is equivalent to 15,000 ng/kg, thousands times higher than the usual dose of 4 ng/kg given to normal volunteers in experimental studies. Endothelial cells are much more sensitive to LPS than epithelial cells, with pg/mL level LPS activating endothelial cells in the presence of blood, compared to the relative resistance of respiratory epithelial cells to μg/mL level LPS [ | |
| Pugin et al., 1993 [ | Human umbilical vein endothelial cells (HUVEC) | Incubated with different dilutions of | nil | nil | nil | HUVECs incubated with different dilutions of LPS for 6 h | In the presence of whole blood, 1000-fold less LPS was required to achieve the level of HUVEC activation (assessed by VCAM-1 upregulation) observed with plasma alone. | Endothelial cells are sensitive to ng/mL LPS in the absence of blood, but much more sensitive even to pg/mL LPS in the presence of blood. | |
| Rodriguez et al., 2003 [ | C57BL/6J, BALB/c and C3H/HeJ mice |
| LPS at a dose of 20 μg/animal was delivered intranasally concomitantly with a second OVA challenge | OVA | 4 μg OVA/1.6 mg aluminum hydroxide | 10 μg OVA/50 μL saline intranasally | Mice were immunized on Days 0 and 7, and challenged on Days14 and 21 intranasally | LPS administration suppresses allergic airway inflammation and cytokine production through a mechanism independent of IL12 or IFNγ Local LPS switched the airway inflammation from eosinophilia to neutrophilia. Local LPS increased AHR by neutrophilic inflammation. | Systemic LPS displayed protective effect, while local LPS displayed pro-inflammatory effect with neutrophilia reaction. |
| Hammad et al., 2009 [ | Radiation-induced chimeric | 10 μg or 100 ng per mouse, in 80 μL PBS, intratracheal | HDM | nil | Intratracheal 100 μg HDM | 80 μL PBS intratracheal with HDM and LPS | TLR4 expression on lung structural cells, but not on DCs, is necessary and sufficient for lung DC activation and for priming of effector T helper responses to HDM. | TLR4 triggering on structural cells in the presence of HDM caused production of TSLP, GM-CSF, IL25 and IL33. The absence of TLR4 on structural cells, but not on hematopoietic cells, abolished HDM-driven allergic airway inflammation. |
nil: not in list.
Figure 1(a) Before sensitization, when the LPS level in the environment is high, each episode of common cold infection (dsRNA) cause no effect on epithelial cells (ECs), but stimulate dendritic cells (DCs) to skew towards Th1 prone except RSV infection, which is Th2 prone. (b) When the LPS level in the environment is low, each episode of common cold infection (dsRNA) then stimulate the epithelial cells to produce proallergic cytokines, such as thymic stromal lymphopoietin (TSLP) and IL33, which would facilitate T cells to produce more IL4, IL5 and IL13, and these Th2 cytokines would work synergistically with dsRNA to stimulate ECs to produce more IL33 and TSLP, forming a positive feedback cycle, and thus shaping the allergic predisposition seen clinically.
Profile of four major players of the hygiene hypothesis model in the presence of high dose LPS before sensitization.
| Cell Type | High Dose LPS | polyI:C or Virus |
|---|---|---|
| Epithelial cells | Minimal or no effect [ | Neutral because allergic inflammation due to TLRs pathway activation was blocked by pre-exposure to high dose LPS [ |
| Dendritic cells | Basically slight Th1 skewing due to high dose LPS with no IL12/IL4 skewing in the context [ | Th1 predominant except RSV infection, which displays Th2 pattern [ |
| Net result: Th1 predominant # | ||
# Here what we call high dose is relative to low dose, but not to the extent of toxic dose as in Table 3. High dose LPS has minimal or no effect on epithelial cells, but will skew the DCs slightly toward Th1 response when no IL12/IL4 skewing in the context, and produce less Th2-promoting mDC2s.On the other hand, the Th2-prone allergic inflammation of polyI:C or virus was blocked by pre-exposure to high dose LPS, and polyI:C or virus will stimulate DCs to produce Th1 predominant cytokines with the exception of RSV infection, which displays Th2 pattern. The net result of polyI:C or virus stimulation in the presence of high dose LPS on DCs and epithelial cells would thus be Th1 predominant.
Profile of four major players of the hygiene hypothesis model in the presence of low dose LPS before sensitization.
| Cell Type | Low Dose LPS | polyI:C or Virus |
|---|---|---|
| Epithelial cells | Minimal or no effect. | Th2 predominant due to TLR3 pathway activation with production of TSLP, IL33, IL25 etc. [ |
| Dendritic cells | Basically slight Th2 skewing due to low dose LPS when no IL12/IL4 skewing in the context [ | Th1 or Th2 skewing, depending on the relative stimulatory force between Th2-prone allergic cytokines, such as TSLP and IL33 [ |
| Net result:Th2 predominant # | ||
# Here what we call high dose is relative to low dose, but not to the extent of toxic dose as in Table 3. Low dose LPS has minimal or no effect on epithelial cells, but will skew the DCs slightly toward Th2 response when no IL12/IL4 skewing in the context. On the other hand, the Th2-prone allergic inflammation of polyI:C or virus was not blocked, or even slightly enhanced by pre-exposure to low dose LPS. polyI:C or virus will stimulate DCs to produce Th1 predominant cytokines with the exception of RSV infection, which displays Th2 pattern. However, Th2-prone signals coming from epithelial cells, such as TSLP and IL33 will skew the DCs toward Th2. The net result of polyI:C or virus stimulation in the presence of low dose LPS on DCs and epithelial cells would thus be Th2 predominant.